Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor

Abstract

The present invention provides a composition comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms. The invention provides a composition which comprises nanoparticulate particles comprising the platelet aggregation inhibitor and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a platelet aggregation inhibitor, or nanoparticles comprising the same, in a pulsatile or continuous manner.

Description

Nanoparticles and controlled release compositions comprising platelet aggregation inhibitors field of invention The present invention relates to compositions and methods for preventing and treating ischemic conditions. In particular, the invention relates to compositions comprising inhibitors of platelet aggregation, and methods of making and using the compositions. In one embodiment of the invention, the composition is in the form of nanoparticles, also comprising at least one surface stabilizer. The invention also relates to new dosage forms for the controlled delivery of platelet aggregation inhibitors. Platelet aggregation inhibitors used in the present invention include cilostazol and salts and derivatives thereof. Background of the invention Intermittent claudication is pain in the legs that occurs when walking and goes away when resting. It occurs because narrowed or blocked arteries reduce blood flow to the legs, resulting in insufficient oxygen levels to the le...

AI Technical Summary

Problems solved by technology

In addition, such frequent administration often requires the attention of health care personnel and thus leads to very high costs associated with platelet aggregation inhibitor therapy

Images